Prostate growth is dependent on circulating androgens, which can be influenced by hepatic function. Liver disease has been suggested to influence prostate cancer (CaP) incidence. However, the effect of hepatic function on CaP outcomes has not been investigated. A total of 1181 patients who underwent radical prostatectomy (RP) between 1988 and 2008 at four Veterans Affairs hospitals that comprise the Shared Equal Access Regional Cancer Hospital database and had available liver function test (LFT) data were included in the study. Independent associations of LFTs with unfavorable pathological features and biochemical recurrence were determined using logistic and Cox regression analyses. Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) levels were elevated in 8.2 and 4.4% of patients, respectively. After controlling for CaP features, logistic regression revealed a significant association between SGOT levels and pathological Gleason sum X7(4 þ 3) cancer (odds ratio ¼ 2.12; 95% confidence interval ¼ 1.11-4.05; P ¼ 0.02). Mild hepatic dysfunction was significantly associated with adverse CaP grade, but was not significantly associated with other adverse pathological features or biochemical recurrence in a cohort of men undergoing RP. The effect of moderate-to-severe liver disease on disease outcomes in CaP patients managed non-surgically remains to be investigated.
Introduction
Prostate adenocarcinoma proliferation is highly dependent on circulating sex steroids, specifically testosterone and dihydrotestosterone, and the binding of these hormones to receptors on prostate cancer (CaP) cells. 1, 2 Poorly differentiated rapidly proliferating CaPs commonly lose much of their dependence on these hormones. Conditions that result in changes in sex steroid production, particularly decreased androgens and/or increased estrogens, can inhibit the growth and development of well-differentiated CaPs, but may have little influence or even an undesirable effect on poorly differentiated prostate tumors. This phenomenon has been shown with finasteride, which decreases the conversion of testosterone to dihydrotestosterone by inhibition of 5-a reductase enzyme. In the Prostate Cancer Prevention Trial, finasteride was found to significantly prevent or delay CaP by almost 25% overall; however, the risk for having high-grade disease, specifically Gleason grade 7-10 tumors, was significantly increased. 3 Though the exact underlying mechanism by which finasteride reduces risk for CaP while simultaneously promoting aggressive disease requires further study; investigators could speculate that reduction of circulating androgens may be, in part, responsible.
Obesity is another condition, which may exert a similar paradoxical effect on CaP incidence. Obese men have increased estradiol levels resulting from increased peripheral conversion of steroids in adipose tissues by the enzyme aromatase. This phenomenon results in an anti-androgenic effect driving down testosterone levels similar to administration of finasteride. Though more recent studies point to other causes for increased risk of advanced CaP in obese men (such as detection bias secondary to PSA hemodilution), 4 some investigators have suggested that obesity decreases the overall rate of CaP development and increases the incidence of more aggressive prostatic tumors through decreased testosterone production, 5, 6 though confirmatory studies are clearly needed.
Hepatic dysfunction, most commonly from excess alcohol consumption, can also result in diminished androgen and increased estrogen effects. [7] [8] [9] [10] Several authors have investigated the effect of alcohol intake on the incidence of CaP and, similar to finasteride administration and obesity, there seems to be a diminished incidence of CaP in alcoholic beverage drinkers implying a protective effect. [11] [12] [13] [14] [15] [16] [17] Hypogonadal effects of alcohol-induced liver disease are similarly ascribed to reduce androgen production and are, thus, suggested to influence development of CaP. However, studies have not investigated the effect of impaired hepatic function on pathological or biochemical outcomes in men being treated surgically for CaP. In this study, we sought to determine whether impaired liver function, pre-operatively, as exemplified by abnormal liver function tests (LFTs), influences the risk for adverse pathological features of CaP or biochemical recurrence, post-operatively, in a multi-ethnic cohort of men undergoing radical prostatectomy (RP) in the equal-access setting of Veterans Affairs hospitals.
Methods
After obtaining institutional review board approval for data abstraction from each institution, demographic and clinicopathological data from 2374 patients who underwent RP from 1988 to 2008 at the Veterans Affairs Medical Centers of Augusta, Georgia; Durham, North Carolina; West Los Angeles, California; and Palo Alto, California were retrospectively collected. These databases comprise the Shared Equal Access Regional Cancer Hospital database. As the distribution of all clinicopathological variables was similar between the four Shared Equal Access Regional Cancer Hospital sites, data from all four sources were combined for analysis. To be included in the study, patients must have the results of at least one pre-operative LFT available, specifically serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), or serum g-glutamyl transferase (SGGT). Men who did not have any available LFT data (n ¼ 1158) were excluded. We also excluded men treated with neoadjuvant radiation/hormonal therapy (n ¼ 35). This resulted in a final study population of 1181. RP specimens were sectioned and evaluated as per standard protocol of each institution by pathologists blinded to the status of hepatic function.
LFT data were analyzed as continuous terms after logarithmic transformation, and normal versus elevated LFT categories according to the following upper limits in normal reference ranges: SGOT ¼ 40 IU l . As continuous terms, associations between LFT and clinicopathological variables were assessed using Spearman's rank test. The distribution of clinicopathological characteristics across LFT categories was compared using w 2 test for categorical variables and Mann-Whitney test for continuous variables. Logistic regression was used to determine the association of LFTs to the following binary outcome variables: pathological Gleason sum X7(3 þ 4), X7(4 þ 3), X8, extracapsular extension, positive surgical margins, and seminal vesicle invasion; only a few men had lymph node metastasis. We adjusted for preoperative PSA level (continuous after logarithmic transformation), biopsy Gleason score grouping (2-6, 3 þ 4, and X4 þ 3), age at surgery (continuous), race (Caucasian, African-American, or other), body mass index (categorical; o25, 25-29.9, 30-34.0, and X35 kg m -2 ), surgery year (continuous), clinical stage (cT1c versus cT2/T3), and surgical center (categorical).
Kaplan-Meier test was used to assess the association of LFTs with biochemical recurrence-free survival. Biochemical progression was defined as one PSA level of 40.2 ng ml -1 , two of 0.2 ng ml -1 , or secondary treatment for a high PSA level after RP.
LFTs were also entered as continuous terms after logarithmic transformation into a Cox proportional hazards regression model adjusting for pre-operative characteristics, as described above, as well as pathological features of CaP including pathological Gleason sum (2-6, 3 þ 4, and X4 þ 3), margin status, extracapsular extension, seminal vesicle invasion, lymph node metastasis, and prostate weight (continuous after logarithmic transformation). To estimate the risk of biochemical progression associated with LFTs, indicator variables for normal versus elevated categories for LFTs were entered into separate Cox models controlling for pre-operative and pathological confounders as described above. Associations with P-values o0.05 were considered statistically significant. All analyses were performed with STATA 10 (Statacorp., College Station, TX, USA).
Results
Demographic and clinicopathological characteristics of the study population are shown in Table 1 After controlling for the various demographic and clinicopathological variables of CaP, logistic regression analysis revealed a significant association between SGOT levels (treated as a logarithmically transformed continuous variable) and pathological Gleason sum X7 (4 þ 3) cancer (odds ratio ¼ 2.12; 95% confidence interval ¼ 1.11-4.05; P ¼ 0.02; Table 2 ) and a marginally significant association between SGOT levels and pathological Gleason sum X8 cancer (odds ratio ¼ 2.03; 95% confidence interval ¼ 0.91-4.52; P ¼ 0.08). Taken as logarithmically transformed continuous terms or categorical terms (normal versus elevated), SGPT and SGGT were not associated with pathological Gleason sum X7 (3 þ 4), X7 (4þ 3), or X8 CaP. Furthermore, there was no association between LFTs and extracapsular extension, positive surgical margin, and seminal vesicle invasion (Table 2) .
Kaplan-Meier test did not reveal any association between elevated LFTs and biochemical recurrence after RP. Likewise, Cox proportional hazards models did not reveal any association between LFTs (continuous or categorical) and recurrence-free survival independent of the various demographic and clinicopathological variables (Table 3) .
Discussion
There is some evidence that hepatic dysfunction may decrease the risk for being diagnosed with CaP though the mechanism for this association is unclear. In the current analysis, we hypothesized that liver dysfunction, as measured by increased LFTs, could possibly decrease the risk for advanced stage disease or decrease the risk of biochemical relapse after surgical extirpation of the prostate. We, however, found that LFTs were not associated with favorable pathological or biochemical outcomes in CaP patients treated surgically. On the contrary, we found a modest association between SGOT levels and high-grade CaP. Thus, at least in RP patients, liver function does not seem to be of value in terms of predicting or affecting cancer-specific outcomes. 
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On the basis of the study population of 1181 patients and an a of 0.05, our analysis was adequately powered (0.89) to detect a 40% difference in survival. Cox regression models for elevated SGOT, elevated SGPT, and both elevated LFTs did not show any increase in recurrence-free survival estimates when compared with individuals with normal LFTs. No such correlation was seen with increased SGGT levels as well; however, only 36% of the participants had SGGT data. In this study, survival end point was defined by the occurrence of biochemical recurrence as measured by post-operative PSA. Though earlier studies show a possible protective effect of hepatic dysfunction for being diagnosed with CaP, liver disease seems to only affect outcomes modestly, if at all, once CaP is diagnosed and treated surgically. Furthermore, despite the high-positive margin rates among VA patients (44%), which is characteristic of high-risk multi-racial populations with predominantly low socioeconomic status, we did not find any association between LFTs and surgical margin status.
The growth of well-differentiated CaPs is thought to be dependent on testosterone. Conversely, resistance to androgens is associated with poorly differentiated and rapidly proliferating tumors. Poorly differentiated cancers would behave aggressively with a larger percentage being high grade, when compared with those that are well differentiated, and, therefore, have a higher recurrence rate post-RP. This was seen in a study by Schatzl et al., 18 which found that higher Gleason sum cancers were associated with decreased circulating testosterone levels. Hepatic dysfunction is associated with decreased peripheral circulating testosterone secondary to its conversion to estrogens. Theoretically, greater conversion to estrogens would then favor the growth of poorly differentiated CaP, while providing inadequate stimulation for proliferation of well-differentiated tumors. This process was described in a paper by Lucia et al. in association with finasteride administration. 19 In that study, an increase in the percentage of incident highgrade CaPs were found in the group of men receiving finasteride. 19 Thus, it is reasonable to hypothesize that a similar biological mechanism may explain how liver dysfunction may be protective for incident well-differentiated tumors, but may be associated with high-grade tumors.
The degree of hepatic dysfunction must also be taken into close consideration when interpreting the results of our study. Severity of liver dysfunction is usually assessed for using the Child-Pugh score, which uses serum total bilirubin, serum albumin, international normalized ratio, presence and severity of ascites, and hepatic encephalopathy to classify patients with chronic liver disease into three categories (Child-Pugh Class A to C) based on worsening survival. 20 Participants that consented to a surgical treatment who had liver disease would only have relatively mild disease (Child-Pugh Class A) because moderate-to-severe hepatic dysfunction (Child-Pugh Class B and C) would exclude the patient from undergoing surgical resection of the tumor. In our study cohort of military veterans, we suspect the most likely cause for liver dysfunction is alcoholic beverage intake. Indeed, cirrhosis is known to decrease circulating testosterone and the degree of reduced testosterone levels has been shown to correlate with the severity of patient's cirrhosis. 10 The majority of study participants had relatively low-grade and well-differentiated CaP. In this population, in which cancer growth is testosterone dependent, decrease in circulating testosterone found in liver cirrhosis may lead to a slower rate of tumor growth; however, men from our study had only mild dysfunction. Thus, the participants in this study are hypothesized to have a decrease in the circulating testosterone levels to a point that suppresses, but does not prevent the growth of well-differentiated, organ-confined CaP, while not selecting for more aggressive poorly differentiated cancer.
We found a significant inverse association between LFTs and pre-operative serum PSA in our study. This is in agreement with earlier studies, which found that cirrhotic patients have significantly lower PSA levels than men with normal liver function. 21, 22 Furthermore, liver dysfunction, which has been shown to influence the development of BPH, is associated with smaller prostate size. 23 This association between liver function and prostate size may further contribute to lower PSA levels in men with hepatic dysfunction. Thus, given that biochemical relapse is defined by post-operative PSA levels, detection of recurrent disease among men with hepatic dysfunction may have been confounded by the hepatic dysfunction-related lowering of PSA. However, the potential effect of liver disease-related lowering of PSA on detection of PSA recurrence requires further study.
Unfortunately, we did not have data on the lifetime cumulative exposure to ingested alcohol among the study participants, which could potentially shed more light on the modest association between LFTs and CaP pathology. Indeed, several studies have found an increased risk for incident CaP among alcoholic beverage drinkers. 13, 24 In fact, distinct types of alcoholic beverages may have differing effects on CaP outcomes, which could have further confounded our study. 17 Moreover, continued use of alcohol intake post-surgery could also affect key dietary nutrients from being absorbed and, therefore, could confound the surgical outcomes observed. Last, serum testosterone levels were not taken pre-operatively among the study participants preventing us from examining the possible correlation between LFTs, alcohol intake, and circulating androgens, and the effect of these associations with CaP outcomes.
Only patients who underwent RP were included in this study. This may exert a selection bias, as poor liver function would impart increased risk for post-operative Liver function and prostate cancer prognosis LL Bañez et al complications, such as bleeding and poor wound healing, excluding such patients from being a candidate for prostatectomy. Thus, the effect of hepatic dysfunction on patients undergoing other treatment modalities, particularly external beam radiation, brachytherapy, and androgen deprivation therapy, deserves further investigation. Subsequently, the effect of liver function on circulating sex hormones and the findings in this study of its effect on CaP have led to a follow-up study, currently underway, to examine the effects of liver function in patients undergoing hormone therapy for treatment of CaP.
Conclusion
In a cohort of men with mild to absent liver disease, all undergoing RP in an equal-access setting, mild hepatic dysfunction was associated with increased risk for highgrade CaP, but did not seem to influence biochemical recurrence post-operatively. The results may differ for patients with significant liver dysfunction who are not typically candidates for RP and would not have been included in this study.
